Ticagrelor – toward more efficient platelet inhibition and beyond

Abstract: Novel antiplatelet drugs, including ticagrelor, are being successively introduced into the therapy of atherothrombotic conditions due to their superiority over a standard combination of clopidogrel with acetylsalicylic acid in patients with acute coronary syndromes (ACS). A P2Y12 receptor antagonist, ticagrelor, is unique among antiplatelet drugs, because ticagrelor inhibits the platelet P2Y12 receptor in a reversible manner, and because it demonstrates a wide palette of advantageous pleiotropic effects associated with the increased concentration of adenosine. The pleiotropic effects of ticagrelor comprise cardioprotection, restoration of the myocardium after an ischemic event, promotion of the release of anticoagulative factors and, eventually, anti-inflammatory effects. Beyond the advantageous effects, the increased concentration of adenosine is responsible for some of ticagrelor’s adverse effects, including dyspnea and bradycardia. Large-scale clinical trials demonstrated that both standard 12-month therapy and long-term use of ticagrelor reduce the risk of cardiovascular events in patients with ACS, but at the expense of a higher risk of major bleeding. Further trials focused on the use of ticagrelor in conditions other than ACS, including ischemic stroke, peripheral artery disease and status after coronary artery bypass grafting. The results of these trials suggest comparable efficacy and safety of ticagrelor and clopidogrel in extra-coronary indications, but firm conclusions are anticipated from currently ongoing studies. Here, we summarize current evidence on the superiority of ticagrelor over other P2Y12 antagonists in ACS, discuss the mechanism underlying the drug–drug interactions and pleiotropic effects of ticagrelor, and present future perspectives of non-coronary indications for ticagrelor.

Keywords: ticagrelor, P2Y12, antiplatelet drugs, myocardial infarction, acute coronary syndromes, pleiotropism

Introduction

Activation of platelets on a ruptured or eroded atherosclerotic plaque is a key event in atherothrombosis, including acute coronary syndromes (ACS) and acute ischemic stroke (AIS). Beyond thrombus formation, activated platelets trigger and disseminate vascular inflammation by exposure and release of pro-inflammatory molecules, thereby contributing to the progression of atherosclerosis. Platelet P2Y12 receptors for adenosine diphosphate (ADP) are essential for platelet activation. For this reason, dual antiplatelet therapy (DAPT) comprising acetylsalicylic acid (ASA) and antagonists of the P2Y12 receptor is widely used to prevent recurrent ischemic events in patients with ACS. Among the P2Y12 antagonists, clopidogrel has been the standard treatment since its approval by the US Food and Drug Administration in 1997. Findings from recent large-scale clinical trials demonstrated that platelet inhibition with a novel and more potent P2Y12 receptor antagonist, ticagrelor, and prasugrel reduced the rate of ischemic events compared to clopidogrel. Subsequently, ticagrelor and prasugrel have been...
recommended as the first line treatment in both patients with ST segment elevation myocardial infarction (STEMI) and non-ST segment elevation ACS at moderate-to-high risk of ischemic events, regardless of the initial treatment strategy. In contrast to clopidogrel and prasugrel, ticagrelor 1) blocks the P2Y12 receptor reversibly, 2) increases the concentration of adenosine, and in contrast to clopidogrel 3) is metabolized independently of the interfing՜sand genetic variability. Therefore, ticagrelor is being increasingly investigated in patients with ACS, as well as in non-coronary indications.

In this review, we briefly present the pharmacokinetics and pharmacodynamics of P2Y12 antagonists, summarize the current evidence on the superiority of ticagrelor over clopidogrel in ACS, discuss the mechanism underlying the drug–drug interactions and pleiotropic effects of ticagrelor, and present future perspectives of non-coronary indications for ticagrelor.

**P2Y12 receptor characteristics, P2Y12 antagonists pharmacokinetics and pharmacodynamics**

P2Y12 receptor is a G-coupled receptor expressed mainly on platelet cells and merely present on microglial cells. Binding of ADP results in receptor activation, inhibition of adenyl cyclase, decrease in cyclic adenosine monophosphate level, and finally platelet aggregation. Expression of P2Y12 receptor may vary due to 1) substitution in the P2Y12R coding gene, 2) qualitative abnormalities of the platelet P2Y12R which result in extensive bleeding disorders, and 3) chronic conditions like diabetes mellitus (DM) and chronic kidney disease (CKD) which are associated with high activity of P2Y12R. Although the scope of P2Y12R functions exceeds beyond platelet activity, the primary function of the P2Y12 receptor includes platelet activation and therefore its inhibition evokes interest in the prevention of thrombotic events.

A summary of pharmacodynamic and pharmacokinetic properties of oral P2Y12 antagonists is presented in Table 1. Clopidogrel is a prodrug. Following oral administration and intestinal absorption of clopidogrel, it is activated by esterases and only 15% of the dose is further metabolized in a two-step process by different hepatic cytochrome P450 (CYP450) isoenzymes. The response to clopidogrel is highly variable. The most important aspects that influence the response to clopidogrel include genetic factors, comorbidities, with an emphasis on DM and chronic renal failure, as well as adjunctive pharmacotherapy, including proton pump inhibitors, calcium-channel blockers, coumarin derivatives and statins. Thus, about one-third of the clopidogrel recipients remain resistant to its anti-aggregatory effect – a phenomenon called high on-treatment platelet reactivity.

A third-generation thienopyridine, prasugrel, is also administered as a prodrug, which needs intestinal and hepatic conversion. However, only one CYP450 step is involved in this process, and prasugrel pharmacokinetics and pharmacodynamics are less dependent on genetic variability. Prasugrel active metabolite achieves inhibition of platelet aggregation (IPA) within 1 hour after administration. Consequently, DAPT using this newer P2Y12 inhibitor results in faster, more consistent, and stronger platelet inhibition.

In contrast to both clopidogrel and prasugrel, ticagrelor is a unique non-thienopyridine P2Y12 antagonist, which does not require metabolic activation, binds to the P2Y12 receptor in a reversible manner, reaches IPA within 30 minutes after administration, and demonstrates pleiotropic effects probably by increasing adenosine concentration and by yet unknown mechanisms. These features likely set ticagrelor in a higher

### Table 1: Pharmacodynamics and pharmacokinetics of oral P2Y12 inhibitors

<table>
<thead>
<tr>
<th></th>
<th>Clopidogrel</th>
<th>Prasugrel</th>
<th>Ticagrelor</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chemical group</td>
<td>Thienopyridine</td>
<td>Thienopyridine</td>
<td>Cyclopentyltriazolopyrimidine</td>
</tr>
<tr>
<td>Dosage (loading; maintenance), mg</td>
<td>300; 75</td>
<td>60; 10</td>
<td>180; 90</td>
</tr>
<tr>
<td>Metabolic activation required</td>
<td>Yes</td>
<td>Yes</td>
<td>No</td>
</tr>
<tr>
<td>CYP responsible for metabolism*</td>
<td>CYP2C19</td>
<td>CYP3A4/5, CYP2B6</td>
<td>CYP3A4</td>
</tr>
<tr>
<td>Metabolism dependent on CYP phenotype</td>
<td>Yes</td>
<td>No</td>
<td>No</td>
</tr>
<tr>
<td>IPA, %</td>
<td>50–70</td>
<td>90</td>
<td>90</td>
</tr>
<tr>
<td>Time to reach IPA, h</td>
<td>2–4 (depends on phenotype)</td>
<td>1</td>
<td>0.5</td>
</tr>
<tr>
<td>Time to reach C&lt;sub&gt;max&lt;/sub&gt;, h</td>
<td>0.5–1</td>
<td>0.5</td>
<td>1.3–2</td>
</tr>
<tr>
<td>Reversible binding to ADP receptor</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
<tr>
<td>Pleiotropism</td>
<td>Yes</td>
<td>Yes</td>
<td>Yes</td>
</tr>
<tr>
<td>Adenosine-related pleiotropism**</td>
<td>No</td>
<td>No</td>
<td>Yes</td>
</tr>
</tbody>
</table>

**Notes:** *Most pharmacodynamically involved CYP; **probably adenosine-related pleiotropism (see “Mechanism underlying the pleiotropic effects of ticagrelor” section). Data from Teng* and Siller-Matula et al.*

**Abbreviations:** CYP, cytochrome P450; IPA, inhibition of platelet aggregation; C<sub>max</sub>, maximal concentration; ADP, adenosine diphosphate.
position among the P2Y12 antagonists, and contribute to the wide spectrum of clinical benefits.

**Superiority of ticagrelor over clopidogrel in ACS**

Table 2 presents a comparison of the efficacy and safety outcomes between ticagrelor and other P2Y12 antagonists in patients with ACS.

The superiority of ticagrelor over clopidogrel has been initially established based on the results of the multicenter, double-blind, randomized PLATO (Platelet Inhibition and Patient Outcomes) study, which compared ticagrelor and clopidogrel for the prevention of cardiovascular (CV) events in 18,624 patients with ACS, with or without ST segment elevation.3 PLATO showed a reduction in the primary efficacy endpoint (a composite of death from vascular causes, acute myocardial infarction [AMI], or stroke) in patients treated with ticagrelor, as compared to those treated with clopidogrel (9.8% vs 11.7%, respectively, \( p < 0.001 \)) at 12 months. Importantly, no significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% vs 11.2%, \( p = 0.43 \)), although ticagrelor was associated with a higher rate of fatal intracranial bleeding, and lower rate of fatal bleeding of other types. The conclusions from PLATO were confirmed in a real-life setting in the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies as well as in several other studies listed in Table 2.13 Additionally, a recent meta-analysis of nine randomized clinical trials that included 106,288 patients showed reduced all-cause mortality, CV mortality, rate of AMI and stent thrombosis with ticagrelor, compared to clopidogrel, while the rate of major bleeding between the two groups was comparable.13

The benefits of long-term administration of DAPT with ticagrelor were demonstrated in the PEGASUS TIMI 54 trial (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54),14 which randomized 21,162 patients who had had AMI 1–3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. Both doses were shown to decrease the composite endpoint of CV death, AMI, or stroke (7.85% vs 9.04%, \( p = 0.008 \) for 90 mg vs placebo, 7.77% vs 9.04%, \( p = 0.004 \) for 60 mg vs placebo) after 33 months of treatment. However, the rate of major bleeding was higher with both doses of ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%, \( p < 0.001 \) for each dose vs placebo), without significant differences in fatal bleeding. Based on

**Table 2 Comparison of the efficacy and safety outcomes between ticagrelor and other P2Y12 antagonists in patients with ACS, with or without ST segment elevation**

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Patients (n)</th>
<th>Follow-up</th>
<th>Efficacy (CV death + stroke + AMI)</th>
<th>Safety (major bleeding)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td>Ticagrelor</td>
<td>Clopidogrel</td>
</tr>
<tr>
<td>Ticagrelor versus clopidogrel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLATO (2009)</td>
<td>18,624</td>
<td>1 year</td>
<td>9.8%</td>
<td>11.7%</td>
</tr>
<tr>
<td>PHILO (2015)</td>
<td>801</td>
<td>1 year</td>
<td>9.0%</td>
<td>6.3%</td>
</tr>
<tr>
<td>SWEDGEHEART (2016)</td>
<td>45,073</td>
<td>2 years</td>
<td>11.7%</td>
<td>22.3%</td>
</tr>
<tr>
<td>Meta-analysis (2017)</td>
<td>106,288</td>
<td>1 year</td>
<td>OR (95% CI) = 0.88 (0.81–0.95)</td>
<td>OR (95% CI) = 1.05 (0.96–1.15)</td>
</tr>
<tr>
<td>Real-world comparison (2017)</td>
<td>401</td>
<td>1 year</td>
<td>0.7%</td>
<td>5.4%</td>
</tr>
<tr>
<td>High-risk patients with ACS (2017)</td>
<td>273</td>
<td>6 months</td>
<td>1.4%</td>
<td>2.9%–3.3%</td>
</tr>
<tr>
<td>ACS and out-of-hospital cardiac arrest (2017)</td>
<td>144</td>
<td>Hospital stay</td>
<td>25.0%</td>
<td>26.2%</td>
</tr>
<tr>
<td>Ticagrelor versus prasugrel</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PRAGUE 1B (2016)</td>
<td>1,230</td>
<td>1 month</td>
<td>4.0%</td>
<td>4.1%</td>
</tr>
<tr>
<td>Meta-analysis (2017)</td>
<td>106,288</td>
<td>1 year</td>
<td>OR (95% CI) = 0.92 (0.78–1.08)</td>
<td>OR (95% CI) = 1.20 (0.95–1.5)</td>
</tr>
<tr>
<td>Real-world comparison (2016)</td>
<td>16,098</td>
<td>3 months</td>
<td>2.9%–3.5%</td>
<td>1.8%–2.5%</td>
</tr>
</tbody>
</table>

**Notes:** Efficacy and safety outcomes are reported as % and significance (\( p \)), or OR and 95% CI. The significant differences are marked in bold.

**Abbreviations:** OR, odds ratio; CI, confidence interval; NS, non significant; CV, cardiovascular; AMI, acute myocardial infarction; ACS, acute coronary syndromes; PLATO, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes; PHILO, Ticagrelor versus Clopidogrel in Japanese, Korean and Taiwanese Patients with Acute Coronary Syndrome; PRAGUE 1B, Prasugrel versus Ticagrelor in Patients with Acute Myocardial Infarction Treated with Primary Percutaneous Coronary Intervention.

The superiority of ticagrelor over clopidogrel has been initially established based on the results of the multicenter, double-blind, randomized PLATO (Platelet Inhibition and Patient Outcomes) study, which compared ticagrelor and clopidogrel for the prevention of cardiovascular (CV) events in 18,624 patients with ACS, with or without ST segment elevation.3 PLATO showed a reduction in the primary efficacy endpoint (a composite of death from vascular causes, acute myocardial infarction [AMI], or stroke) in patients treated with ticagrelor, as compared to those treated with clopidogrel (9.8% vs 11.7%, respectively, \( p < 0.001 \)) at 12 months. Importantly, no significant difference in the rates of major bleeding was found between the ticagrelor and clopidogrel groups (11.6% vs 11.2%, \( p = 0.43 \)), although ticagrelor was associated with a higher rate of fatal intracranial bleeding, and lower rate of fatal bleeding of other types. The conclusions from PLATO were confirmed in a real-life setting in the Swedish web-system for enhancement and development of evidence-based care in heart disease evaluated according to recommended therapies as well as in several other studies listed in Table 2.13 Additionally, a recent meta-analysis of nine randomized clinical trials that included 106,288 patients showed reduced all-cause mortality, CV mortality, rate of AMI and stent thrombosis with ticagrelor, compared to clopidogrel, while the rate of major bleeding between the two groups was comparable.13

The benefits of long-term administration of DAPT with ticagrelor were demonstrated in the PEGASUS TIMI 54 trial (Prevention of Cardiovascular Events in Patients with Prior Heart Attack Using Ticagrelor Compared to Placebo on a Background of Aspirin-Thrombolysis in Myocardial Infarction 54),14 which randomized 21,162 patients who had had AMI 1–3 years earlier to ticagrelor at a dose of 90 mg twice daily, ticagrelor at a dose of 60 mg twice daily, or placebo. Both doses were shown to decrease the composite endpoint of CV death, AMI, or stroke (7.85% vs 9.04%, \( p = 0.008 \) for 90 mg vs placebo, 7.77% vs 9.04%, \( p = 0.004 \) for 60 mg vs placebo) after 33 months of treatment. However, the rate of major bleeding was higher with both doses of ticagrelor (2.60% with 90 mg and 2.30% with 60 mg) than with placebo (1.06%, \( p < 0.001 \) for each dose vs placebo), without significant differences in fatal bleeding. Based on
the PEGASUS TIMI 54 trial, it seems that patients with generally low bleeding risk might benefit from prolonged treatment with ticagrelor over 12 months. However, additional research is required to define the target population for this treatment strategy.

The promising results of the PLATO and PEGASUS TIMI 54 trials were not confirmed in the PHILO study (Phase the International Study of Ticagrelor and Clinical Outcomes in Asian ACS Patients) and a substudy in the Asian cohort of the PLATO-US, undermining the benefits of ticagrelor in Asian patients. Both in PHILO and in the Asian cohort of PLATO-US there was a tendency toward more death, AMI, and AIS in patients treated with ticagrelor compared with clopidogrel (hazard ratio, 1.47; 95% confidence interval [CI]: 0.88–2.44 in PHILO and 0.68–2.01 in the PLATO-US cohort). Additionally, there were more major bleedings on ticagrelor in the PHILO study, whereas the bleeding rate in the PLATO-US cohort study was not increased, and comparable with the rest of the PLATO study. Nevertheless, the higher rate of ischemic events in Asian patients calls for further investigation regarding the benefits of ticagrelor administration in Asian populations.

Ticagrelor was not superior to clopidogrel when combined with anticoagulant therapy. A study that compared a double therapy comprising ticagrelor and warfarin with a triple therapy comprising ASA, clopidogrel, and warfarin demonstrated a comparable rate of thrombotic and bleeding events in both groups. Additionally, in the GEMINI ACS-1 (A Study to Compare the Safety of Rivaroxaban Versus Acetylsalicylic Acid in Addition to Either Clopidogrel or Ticagrelor Therapy in Participants with Acute Coronary Syndrome) trial, the rate of thrombotic and bleeding events for rivaroxaban versus aspirin was similar in the ticagrelor group compared with the clopidogrel group. However, the choice of clopidogrel or ticagrelor during the trial was not randomized, but was rather based on the investigator’s preference. These analyses are exploratory and leave space for various hypotheses. In the absence of sufficient efficacy and safety data, the use of ticagrelor or prasugrel as a part of triple therapy is not recommended.

Indirect comparison of the two cornerstone studies comparing the efficacy of ticagrelor and prasugrel (PLATO and TRITON TIMI 38) revealed that prasugrel results in greater reduction of PLATO-defined primary endpoints (overall CV death, AMI, ischemic stroke) and mortality in STEMI groups, with no difference in primary endpoint in patients with non-ST segment elevation myocardial infarction (NSTEMI; Figure 1). Moreover, prasugrel increased the

![Figure 1](https://www.dovepress.com/)

**Figure 1** Ticagrelor versus prasugrel – efficiency and safety comparison.

**Notes:** Differences between (A) PLATO-defined overall primary endpoint risk (myocardial infarction, stroke, death from vascular causes); (B) non-CABG-associated major bleeding risk; (C) PLATO-defined primary endpoint risk in NSTE-ACS patients; (D) PLATO-defined primary endpoint risk in STEMI patients; and (E) PLATO-defined overall mortality risk among PLATO and TRITON TIMI (Prasugrel versus Clopidogrel in Patients with Acute Coronary Syndromes) 38 studies.

**Abbreviations:** RRR, relative risk reduction; NNT, number needed to treat; RRI, relative risk increase; NNH, number needed to harm; CABG, coronary artery bypass graft; NSTE-ACS, non-ST-elevation acute coronary state; STEMI, ST segment elevation myocardial infarction.
risk of non-coronary artery bypass graft (CABG)-associated major bleeding. However, two studies and one meta-analysis which compared ticagrelor and prasugrel directly in terms of the reduction of PLATO-defined efficacy and safety endpoints showed no differences in CV mortality, the rate of AMI and AIS at 1 and 3 months.\textsuperscript{16–18} Importantly, the latter study and the meta-analysis showed reduced rate of stent thrombosis in patients receiving prasugrel, which, however, did not translate into reduced mortality.\textsuperscript{20,21} The reduced rate of stent thrombosis on prasugrel may be due to stronger and more rapid platelet inhibition by prasugrel, compared to ticagrelor.\textsuperscript{22} Interestingly, in patients with AMI and type 2 DM, ticagrelor seems to demonstrate greater inhibition of ADP-induced platelet reactivity in comparison to prasugrel, in both the acute and chronic phases of treatment.\textsuperscript{23}

The difference in bleeding risk between ticagrelor and prasugrel remains unclear (Table 2). The previously mentioned meta-analysis demonstrated that ticagrelor is associated with a numerically, albeit nonsignificant, lower risk of major bleeding than prasugrel during 1 year follow-up.\textsuperscript{15} However, a real-world comparison of ticagrelor and prasugrel in 16,098 patients with ACS demonstrated a significantly lower rate of major bleeding events on prasugrel during 1-month follow-up.\textsuperscript{24} More studies are required to identify the P2Y12 antagonist associated with the lowest bleeding rate. Interestingly, a trial in which recombinant activated factor VII, fibrinogen concentrate, and factor XIII concentrate were used to overcome antiplatelet effect by acting on fibrin formation or fibrinolysis may point to the cessation of ticagrelor-related unrestrained bleeding.\textsuperscript{25}

**Ticagrelor drug–drug interactions in ACS**

Among interactions with other drugs, concomitant use of ticagrelor with morphine, statins, and digoxin seems relevant.\textsuperscript{4} Morphine has been reported to reduce the absorption of ticagrelor by its inhibitory effect on gastric motility.\textsuperscript{26} Studies performed on patients with AMI receiving ticagrelor and either morphine or placebo demonstrated diminished and delayed antiplatelet effect in the morphine group. Additionally, a clinically relevant decrease of maximal serum concentrations of both ticagrelor and its active metabolite and prolonged clearance of ticagrelor were observed.\textsuperscript{27,28} Interestingly, in healthy volunteers a similar decrease of concentration of ticagrelor achieved by a comparable dose of morphine was observed, although platelet inhibition remained adequate.\textsuperscript{29} It is likely that the publication of the results of IMPRESSION (Influence of Morphine on Pharmacokinetics and Pharmacodynamics of Ticagrelor in Patients with Acute Myocardial Infarction) trial will elucidate this interaction.\textsuperscript{30}

In addition, morphine causes, via a similar mechanism, significant decrease in the action of clopidogrel.\textsuperscript{31} Current European Society of Cardiology guidelines for the management of AMI recommend intravenous morphine titration in severe pain, however indicating the possibility of failure of antiplatelet effect due to interaction with morphine.\textsuperscript{32}

Revision of results of the PLATO trial which focused on the interaction between ticagrelor and statins concluded that co-administration of ticagrelor and statins decreased both vascular and all-cause mortality, compared to clopidogrel and statins.\textsuperscript{29} Increased concentration of simvastatin in the presence of ticagrelor was confirmed also in healthy volunteers.\textsuperscript{33} These results have been attributed to the fact that ticagrelor, in contrast to clopidogrel, weakly inhibits CYP450 3A4 and delays metabolism of certain statins, especially simvastatin. Both ticagrelor and rosuvastatin were shown to increase the concentration of adenosine in animal models, which may further contribute to the beneficial effect of their co-administration.\textsuperscript{34,35} Nevertheless, a series of case studies have reported an increased risk of rhabdomyolysis when ticagrelor was co-administered with high-dose statins in patients with CKD, suggesting that the ticagrelor–statins interaction may be clinically relevant in particular patient populations.\textsuperscript{36,37}

The co-administration of ticagrelor with digoxin warrants caution as well. Because ticagrelor is a weak inhibitor of P-glycoprotein, which is involved in the metabolism of digoxin, the concentration of digoxin may increase once ticagrelor is initiated. Hence, in patients treated with ticagrelor the concentration of digoxin should be monitored.\textsuperscript{38}

**Genetic polymorphism**

The genetic background of ticagrelor response has been investigated previously in several pharmacogenetics studies, but the genetic determination of ticagrelor response in humans still remains unknown. The PLATO trial demonstrated that ticagrelor reduces the rate of a combined endpoint of CV death, AMI, or stroke with no increase in the incidence of major bleeding as compared to clopidogrel, irrespective of cytochrome P450 2C19 (CYP2C19) and adenosine triphosphate (ATP) binding cassette subfamily B (ABCB1) genetic polymorphisms.\textsuperscript{39} In the genetic substudy of the PLATO trial, a two-phase design was used for a genome-wide association study (GWAS): a discovery phase, which consisted of 3,998 individuals genotyped, and a replication phase of an additional 6,015 individuals. The GWAS results on ticagrelor pharmacokinetics in a large cohort of
ticagrelor-treated ACS patients showed an association of three different genetic loci (SLCO1B1-rs4149056, CYP3A4-rs62471956, and UGT2B7-rs61361928) with ticagrelor levels. Importantly, the modest genetic impact on plasma levels of ticagrelor and the active metabolite of ticagrelor (AR-C124910XX [ARC]) did not translate into effect on any efficacy (ie, CV death, MI, and stroke) or safety endpoints (ie, non-CABG-related bleeds or investigator-reported dyspnea). In a recent study, the impact of genetic variations within both ITGA2B and ITGB3 encoding genes on ex vivo antplatelet effects of ticagrelor in Chinese healthy subjects was studied. In 28 carriers of ITGA2B rs5911 GG genotype was associated with lower level of platelet ADP-induced platelet activation after incubation with ticagrelor. The study showed that the SNP can decrease the ex vivo antplatelet activity of ticagrelor, especially at low concentration, though the baseline platelet activity was not affected by the polymorphism. However, the ITGB3 rs4642 or rs4634 polymorphisms had no effect on either the baseline platelet activity or the ex vivo antplatelet effect of ticagrelor. In another study, the same group of researchers further evaluated a population of 196 healthy Chinese volunteers in order to analyze the association between platelet reactivity with or without ticagrelor and nine P2Y12 SNPs (rs1907637 C.T, rs79320243 A.G/htSNP, rs10935842 A.T/htSNP, rs6787801 T.C/htSNP, rs6801273 A.G, rs16863323 G.A, rs2046934 T.C, rs6785930 C.T, and rs6809699 G.T/htSNP) and the GNB3 rs5443 C.T polymorphism. However, genetic variations in P2Y12 and GNB3 were not associated with interindividual variability in platelet inhibition after partial ex vivo blockade with ticagrelor. The abovementioned observations stand in line with the first study, which observed that SNPs in P2Y12, P2Y1, and ITGB3 do not affect ticagrelor-induced inhibition of ADP-induced platelet aggregation. In another study conducted in healthy Chinese male subjects, eight different SNPs within PEAR1 gene were evaluated in order to analyze their association with in vitro platelet reactivity and ticagrelor pharmacokinetics. It was found that PEAR1 rs12041331 polymorphism is associated with in vitro antplatelet activity of ticagrelor but no significant difference in ticagrelor pharmacokinetics with the rs12041331 genotype was observed. Minor homozygotes of two SNPs (rs12041331, rs12566888) exhibited statistically significant lower maximal platelet activation and minor allele carriers of rs4661012 polymorphism exhibited statistically significant higher maximal platelet activation. PEAR1 intronic variant rs12041331 AA genotype and 3′-UTR variant rs4661012 GG genotype were associated with an increased IPA after in vitro ticagrelor incubation at low and high concentrations, respectively. However, the mechanisms by which rs12041331 polymorphism influences ticagrelor response remain unknown. No significant difference in the pharmacokinetic parameters of ticagrelor and ARC were observed among PEAR1 genotypes of candidate SNPs. At present, there are no data supporting any impact of genetic polymorphisms in the pharmacokinetics of ticagrelor on clinical outcomes of patients.

**Mechanism underlying the pleiotropic effects of ticagrelor**

The results of the PLATO trial were embraced with growing interest in the extra-platelet effects of ticagrelor. Ticagrelor administration was shown to be associated with the increased concentration of adenosine reuptake by blocking human equilibrative nucleoside transporter 1, and 2) increased release of ATP, subsequently transformed into adenosine.

Although ticagrelor was proved to elevate serum adenosine levels only in higher doses than standard, a similarity between part of pleiotropic effects exerted by ticagrelor and those mediated by adenosine was proved and described. This may suggest that some pleiotropic effects of ticagrelor are achieved via adenosine-dependent mechanism. Effects induced by an increased concentration of adenosine and stimulation of adenosine receptors (A1–A3) are summarized in Table 3. Comparably, probable adenosine-dependent pleiotropic effects of ticagrelor together with pleiotropic mechanisms of unknown origin and mechanisms underlying the adenosine inhibition reuptake are presented in Figure 2.

The first described pleiotropic effect was decreased death rate in patients with ACS receiving ticagrelor (PLATO subgroup) who presented with sepsis or pulmonary infection. This phenomenon was proposed to be based on adenosine-related depletion of pro-inflammatory factors by acting on A2A and A2B adenosine receptors, as well as on decreased platelet reactivity, and thus prevention of disseminated intravascular coagulation. In another study, vasodilation of coronary arteries and increased coronary blood flow velocity (CBFV) were described in patients with NSTEMI undergoing percutaneous coronary intervention. Ticagrelor exhibited higher maximal CBFV/baseline CBFV ratio than prasugrel at increasing concentrations of adenosine infusion rate, confirming that the increased CBFV on ticagrelor is associated with the inhibition of adenosine reuptake. In a study performed on diabetic rats, ticagrelor in combination
Table 3 Effects induced by stimulation of membrane-bound adenosine receptors (A1–A3)

<table>
<thead>
<tr>
<th>Adenosine receptors</th>
<th>Ticagrelor-relevant role</th>
<th>Impact on cell cAMP</th>
<th>Concentration of adenosine required for activation</th>
</tr>
</thead>
<tbody>
<tr>
<td>A1</td>
<td>• Coronary vessel spasm</td>
<td>Decrease</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>• Promotion of neutrophil chemotaxis and phagocytosis</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Negative chronotropic effect</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• GFR decrease</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2a</td>
<td>• Coronary vessel dilation</td>
<td>Increase</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>• EPC migration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inhibition of platelet activation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Dyspnea</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inhibition of neutrophil trafficking, granule release, and production of inflammatory mediators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A2b</td>
<td>• Coronary vessel dilation</td>
<td>Increase</td>
<td>High</td>
</tr>
<tr>
<td></td>
<td>• Inhibition of platelet activation</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inhibition of neutrophil trafficking, granule release</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Inhibition of production of inflammatory mediators</td>
<td></td>
<td></td>
</tr>
<tr>
<td>A3</td>
<td>• Coronary vessel spasm</td>
<td>Decrease</td>
<td>Low</td>
</tr>
<tr>
<td></td>
<td>• EPC migration</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Promotion of neutrophil chemotaxis and phagocytosis</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Abbreviations: cAMP, cyclic adenosine monophosphate; GFR, glomerular filtration rate; EPC, endothelial progenitor cell.

with rosuvastatin decreased the infarct size due to more potent adenosine-dependent myocardial reperfusion. Ticagrelor was shown to increase the concentration of (cluster of differentiation) CD34+/CD133+ endothelial progenitor cells (EPC) in peripheral blood, which are responsible for endothelial regeneration in patients after ACS. The mechanism underlying the increased concentration of EPC is adenosine-modulated migration of EPC instigated by activation

Figure 2 Mechanisms underlying the probable adenosine-dependent and non-adenosine-dependent pleiotropic effects of ticagrelor.

Abbreviations: ICaL, L-type Ca(2+)+ currents in cardiomyocytes; PAI, plasminogen activation inhibitor; EGF, endothelial growth factor; IL-10, interleukin 10; hENT1, human equilibrative nucleoside transporter 1; ATP, adenosine triphosphate; ADP, adenosine diphosphate; VSMC, vascular smooth muscle cells.
of A2A and A3 receptors as well as increased production of endothelial growth factor, interleukin-8 and angiopoietin-1 in endothelial cells, monocytes, and macrophages.66–69 Ticagrelor was also shown to inhibit differentiation of osteoclasts and promote differentiation of osteoblasts via adenosine A2A receptors in vitro.60 Another pleiotropic effect of ticagrelor includes reduced expression and activity of tissue factor and plasminogen activator inhibitor-1 in left atrium appendage endocardial cells isolated from patients with atrial fibrillation, which might translate into reduced risk of stroke and other ischemic events due to thrombus formation in the left atrium.61 On the contrary, ticagrelor has been proved to reduce L-type Ca(2+) current density in rat ventricular myocytes as well as to decrease sarcomere shortening of electrically stimulated cardiomyocytes.62

The increased serum concentration of adenosine seems to be responsible also for ticagrelor-related adverse effects, including dyspnea, ventricular pauses, bradycardia, and bradyarrhythmias. Table 4 summarizes the most frequent adverse effects of ticagrelor in patients with ACS, coronary artery disease, and pulmonary disease (asthma, chronic obstructive pulmonary disease [COPD]). Dyspnea during ticagrelor administration and during simultaneous adenosine infusion was confirmed in numerous studies.63–65 Dyspnea is caused by adenosine acting on A1 and A2A receptors present on C fibers of vagal nerve causing bronchoconstriction.66 Ticagrelor-related dyspnea is described as sudden and unexpected air hunger or unsatisfied inspiration, and in most cases is recognized as mildly intense.67 The diagnosis of ticagrelor-related dyspnea is based on exclusion of other causes of dyspnea. Occurrence of dyspnea varies among trials and depends mainly on the length of administration and dosage of ticagrelor. For example, dyspnea was the reason for ticagrelor discontinuation in 2%–9% ACS patients,68 whereas dyspnea was not observed in healthy elderly volunteers and mild asthma or mild-to-moderate COPD patients.65 The lack of dyspnea in the latter study was probably due to short duration of the trial.

Bradycardia as well as ventricular pauses are side effects of adenosine-related stimulation of adenosine A1 receptor present in heart tissue.69 Bradycardia is recognized as a side effect of all oral P2Y12 antagonists; however, it seems to occur more often on ticagrelor. Differences in the incidence of bradycardia in various studies depend on the definition of “bradycardia” (any decrease in the heart rate versus heart rate below 60 beats per minute). Due to chronotropic effect, ticagrelor decreases the heart rate in all patients, but only in a few cases does ticagrelor cause clinically relevant bradycardia. For example, in 300 patients with AMI, ticagrelor was associated with double the risk of bradycardia (80 patients) than with clopidogrel (32 patients).70 It is not known, however, which clinical event described as bradycardia met the clinical definition of bradycardia, as its incidence varies significantly amidst the trials (PHILO, PLATO, PEGASUS), where bradycardia incidence varied from 1.5% to 7%. Nevertheless, several cases were reported where ticagrelor induced development of secondary degree type 2 block and complete atrioventricular block.71,72

In a study of PLATO 5.8% of patients developed asymptomatic, sinusoid ventricular pauses (>3s) during the first week of treatment, which ceased with time.73 In the

Table 4 Incidence of the most frequent adverse effects of ticagrelor in patients with acute coronary syndrome, coronary artery disease, and pulmonary disease (asthma, COPD)

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Patients (n)</th>
<th>Follow-up</th>
<th>Dyspnea (%)</th>
<th>Bradycardia (%)</th>
<th>Ventricular pauses (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Acute coronary syndromes</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PLATO (2009)</td>
<td>18,624</td>
<td>1 year</td>
<td>13.80</td>
<td>7.10</td>
<td>5.80</td>
</tr>
<tr>
<td>PHILO (2015)</td>
<td>801</td>
<td>1 year</td>
<td>5.70</td>
<td>2.80</td>
<td>0</td>
</tr>
<tr>
<td>PEGASUS TIMI 54 (90 mg) (2015)</td>
<td>13,946</td>
<td>33 months</td>
<td>18.9</td>
<td>2.04</td>
<td>18.9</td>
</tr>
<tr>
<td>PEGASUS TIMI 54 (60 mg) (2015)</td>
<td>13,946</td>
<td>33 months</td>
<td>15.4</td>
<td>2.32</td>
<td>15.4</td>
</tr>
<tr>
<td>DISPERSE 2 (2010)</td>
<td>984</td>
<td>3 months</td>
<td>13.0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Ticagrelor versus clopidogrel in non-ST-elevation acute coronary syndromes (2016)</td>
<td>149</td>
<td>1 year</td>
<td>N/A</td>
<td>54</td>
<td>N/A</td>
</tr>
<tr>
<td>Ticagrelor and bradycardia: a nested case-control study (2015)</td>
<td>700</td>
<td>2 years</td>
<td>N/A</td>
<td>20</td>
<td>N/A</td>
</tr>
<tr>
<td>Coronary artery disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DISPERSE 1 (2010)</td>
<td>200</td>
<td>1 month</td>
<td>14.1</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>ONSET/OFFSET (2009)</td>
<td>123</td>
<td>6 weeks</td>
<td>38.60</td>
<td>N/A</td>
<td>N/A</td>
</tr>
<tr>
<td>Pulmonary disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Healthy volunteers, asthma, or COPD patients (2013)</td>
<td>40</td>
<td>1 week</td>
<td>0</td>
<td>N/A</td>
<td>N/A</td>
</tr>
</tbody>
</table>

Abbreviations: N/A, not applicable; COPD, chronic obstructive pulmonary disease; PLATO, Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes; PHILO, Ticagrelor versus Clopidogrel in Japanese, Korean, and Taiwanese Patients with Acute Coronary Syndrome; PEGASUS TIMI 54, Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction; DISPERSE, Antiplatelet Therapy in Acute Coronary Syndromes: Focus on Ticagrelor; ONSET/OFFSET, Randomized Double-Blind Assessment of the ONSET and OFFSET of the Antiplatelet Effects of Ticagrelor versus Clopidogrel in Patients with Stable Coronary Artery Disease.
PHILO and PEGASUS trials the occurrence of ventricular pauses was 0% and 1.6%, respectively, making ventricular pauses a clinically irrelevant complication. Noteworthy, in one case report both bradycardia and dyspnea were reversed using aminophylline, suggesting that administration of aminophylline might counteract the adenosine-related adverse effects of ticagrelor.74

**Ticagrelor in non-coronary indications**

Major clinical trials involving ticagrelor in non-coronary indications are included in Table 5.

**Ischemic stroke and transient ischemic attacks**

Major evidence of benefits of ticagrelor in AIS or transient ischemic attacks (TIA) arises from the SOCRATES trial (Acute Stroke or Transient Ischemic Attack Treated with Aspirin or Ticagrelor and Patient Outcomes). In SOCRATES, ticagrelor was not superior over ASA in terms of efficacy outcomes in any group of patients. Moreover, both drugs were associated with comparable risk of bleeding and other adverse effects, except for more common dyspnea among patients treated with ticagrelor.75 Noteworthy, a subanalysis of the SOCRATES results in Asian patients compared with non-Asian patients demonstrated equal efficacy of ticagrelor in both groups, but a lower risk of major hemorrhage in Asian patients receiving ticagrelor.76 The beneficial effects of ticagrelor were hypothesized to be associated with the prior long-term use of ASA, which would result in transient DAPT.77,78 In the absence of no clear explanation, as of today, ticagrelor has not been included in the recent guidelines of secondary prevention of stroke.79,80

**Peripheral arterial disease (PAD)**

The use of ticagrelor seems to be associated with a reduced risk of PAD progression among patients with prior AMI. A summary of the previous reports could not firmly demonstrate the superiority of either ticagrelor or clopidogrel in the treatment and prevention of the complications of PAD.81–83 Ultimately, results of the EUCLID (Examining Use of Ticagrelor in Peripheral Artery) trial conclude that both drugs have a comparable efficacy and safety profile, and that there are no differences in adverse effects.84 Nevertheless, novel antiplatelet agents have not yet been introduced in routine pharmacotherapy of PAD.85

**Coronary artery bypass grafting**

Antithrombotic therapy following the procedure of coronary artery bypass grafting is generally based on ASA. Nevertheless, graft failure due to thrombosis occurs in up to 10% of cases and therefore P2Y12 inhibitors are incrementally introduced in patients after CABG. A retrospective observation of 705 patients suggests that exposure to ticagrelor shortly before CABG is associated with a higher risk of hemorrhagic complications. This effect was not observed when ticagrelor was discontinued 3 days prior to surgery.86 A study focusing on the turnover of platelets after CABG suggests that ticagrelor is more efficient than clopidogrel in patients, in whom rapid supply of young platelets occurs.87 A comprehensive insight into the use of ticagrelor after CABG is anticipated from results of the current TiCAB (Ticagrelor in CABG) trial, which aims to compare the efficacy and safety of ticagrelor and ASA after CABG.88

**Conclusion**

Ticagrelor has the potential to revolutionize the treatment of coronary artery disease and ACS due to reduction of CV death as proved in the PEGASUS TIMI 54 trial, when implemented as a component of DAPT. Ticagrelor seems to demonstrate more potent platelet inhibition in ACS patients with DM and/or COPD, as compared with prasugrel, at equal bleeding risk.12,89 Nevertheless, the underperformance of ticagrelor in Asian population shown in the PHILO study needs further

**Table 5** Ticagrelor in non-coronary indications

<table>
<thead>
<tr>
<th>Study (year)</th>
<th>Study design</th>
<th>Patients (n)</th>
<th>Follow-up (median)</th>
<th>Efficacy, OR (95% CI)</th>
<th>Safety (major bleeding), OR (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>EUCLID (2017)</td>
<td>Ticagrelor versus clopidogrel in PAD</td>
<td>13,855</td>
<td>30 months</td>
<td>1.02 (0.92–1.13), p=0.65</td>
<td>1.10 (0.84–1.43), p=0.49</td>
</tr>
<tr>
<td>SOCRATES (2016)</td>
<td>Ticagrelor versus ASA in acute ischemic stroke and TIA</td>
<td>13,199</td>
<td>90 days</td>
<td>0.87 (0.76–1.00), p=0.45</td>
<td>0.83 (0.52–1.34), p=0.45</td>
</tr>
<tr>
<td>TiCAB (2016)</td>
<td>Ticagrelor versus ASA after CABG</td>
<td>500+</td>
<td>12 months (designed)</td>
<td>Currently ongoing</td>
<td></td>
</tr>
</tbody>
</table>

**Abbreviations:** PAD, peripheral artery disease; ASA, acetylsalicylic acid; TIA, transient ischemic attack; CABG, coronary artery bypass grafting; OR, odds ratio; CI, confidence interval; EUCLID, Ticagrelor versus Clopidogrel in Symptomatic Peripheral Artery Disease; SOCRATES, Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack; TiCAB, A Randomized, Parallel Group, Double-Blind Study of Ticagrelor Compared with Aspirin for Prevention of Vascular Events in Patients Undergoing Coronary Artery Bypass Graft Operation; Rationale and Design of the Ticagrelor in CABG (TiCAB) trial: An Investigator-Initiated trial.
investigation. At present, no genetic polymorphisms influencing the metabolism of ticagrelor have been identified to clarify the differences in the efficacy/safety profile of ticagrelor depending on race and comorbidities. The role of ticagrelor in patients with stroke/TIA, PAD, and post-CABG remains limited, as no superiority of ticagrelor over clopidogrel has been shown. Nevertheless, the decreased reapptake of adenosine, which is likely responsible for ticagrelor pleiotropic effects, strengthens the role of ticagrelor in long-term antiplatelet therapy in patients with ACS, as well as in non-ACS indications. For example, ticagrelor might be beneficial in sepsis, as it decreases the concentration of inflammatory biomarkers and modulates the formation of fibrin clots. Regarding the unique pharmacokinetic and pharmacodynamics properties of ticagrelor, as well as the not yet entirely clear pleiotropic effects, ticagrelor remains an active research topic. Once the mechanisms underlying ticagrelor’s mode of action are clarified in vivo, the indications of ticagrelor administration are likely to expand.

Disclosure
Research subject was implemented with CEPT infrastructure financed by the European Union – the European Regional Development Fund within the Operational Program “Innovative economy” for 2007–2013. The study was supported financially as part of the research grant from the National Science Center OPUS research grant (grant number 2013/11/B/NZ7/01541). The authors report no other conflicts of interest in this work.

References


Therapeutics and Clinical Risk Management

Publish your work in this journal

Therapeutics and Clinical Risk Management is an international, peer-reviewed journal of clinical therapeutics and risk management, focusing on concise rapid reporting of clinical studies in all therapeutic areas, outcomes, safety, and programs for the effective, safe, and sustained use of medicines. This journal is indexed on PubMed Central, CAS, EMBase, Scopus and the Elsevier Bibliographic databases. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: http://www.dovepress.com/therapeutics-and-clinical-risk-management-journal

Kubisa et al


